Acutaas Chemicals Ltd Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q2 FY26 earnings call analysis: revenue, margin, capex, fundraise and order book outlook from management commentary.
Published 5 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹26.9K Cr
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
From Acutaas Chemicals Ltd's Q2 FY26 earnings-call transcript · updated 23 Aug 2026.
Price
₹3,169
Market Cap
₹26.9K Cr
P/E Ratio
69.6
How does Acutaas Chemicals Ltd rank in Pharmaceuticals & Biotechnology?
Compare Acutaas Chemicals Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Acutaas Chemicals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹433 Cr, net profit ₹134 Cr.
Full financials →📊 Revenue & Sales Performance
- →The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26.
- →Higher growth is expected from the CDMO business segment compared to traditional Pharma Intermediates.
- →Electrolyte additives segment is expected to start contributing from Q4 FY '26 and more significantly in FY '27, with full visibility on capex and products.
- →Semiconductor JV in South Korea is projected to start commercial production in H2 FY '27, contributing to revenue thereafter.
- →Specialty Chemicals segment is expected to grow around 10-15% in FY '26.
- →No specific revenue disclosure for new segments, but significant growth drivers identified in CDMO, battery chemicals, and semiconductor chemicals in the coming years.
- →Growth is supported by expanding product portfolio focusing on higher-margin products for sustainable growth.
- →Capacity ramp-up, especially Block 3 and new plants, expected to enhance volumes gradually over 2-3 years.
See what Acutaas Chemicals Ltd said on profitability & margins — free account, 30 seconds.
🏗️ Capital Expenditure Plans
- →FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
- →Major growth capex includes INR 180 crores for electrolyte additive plant at Jaghadia and INR 30 crores for pilot plant at Sachin.
- →Electrolyte additive capex expected to complete by Q4 FY '26 and start contributing from Q4 FY '26, fully ramping by FY '27.
- →South Korea JV (Indichem) capex underway, commercial production expected in H2 FY '27; Acutaas holds 75% stake.
- →Beyond FY '26, all planned growth capex expected to be completed; future capex to be mainly maintenance.
- →Additional capacity expansion in electrolyte additives possible depending on business development but no announcements yet.
- →Asset turnover target from capex approximately 2.5x over about 3 years.
See what Acutaas Chemicals Ltd said on fundraising & capital structure — free account, 30 seconds.
📋 Order Book & Pipeline
- →Validation batches for new CDMO contracts have been sent during the quarter.
- →Commercial production for these new CDMO products is expected to start by the last quarter of FY '26, subject to regulatory approvals.
- →Full visibility exists for the CDMO business for the current year and projections for the next years, indicating a healthy order book.
- →The Block 3 at Ankleshwar, commissioned last year, is operational and catering to projected customer requirements.
- →For electrolyte additives, the planned capacity (2,000 metric tons each for VC and FEC) is based on signed contracts, providing full visibility on demand.
- →Overall, multiple products and customers across segments maintain a diversified and robust order pipeline.
- →The company is confident of sustaining a 25% revenue growth driven by existing and upcoming contracts.
Key Metrics
How does Acutaas Chemicals Ltd rank vs peers in Pharmaceuticals & Biotechnology?
Pro featureSee full Pharmaceuticals & Biotechnology sector rankings
Continue your research
What Acutaas Chemicals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- ALIVUS (Q2 FY26)
Capex for H1 FY '26 was INR113 crores; Q2 alone INR61 crores. Key concall takeaways from Alivus Life's Q2 FY26 earnings call — and how it ranks against sector…
- Solara Active Pharma Sciences Ltd (Q2 FY26)
Current facility capacity utilization is about 70%, with capacity available to serve new customers. Key concall takeaways from Solara Active's Q2 FY26 earnings…
- SUNPHARMA (Q2 FY26)
India formulation sales grew 11% in Q2, outpacing Indian Pharmaceutical Market (IPM) growth mainly driven by volume and new product launches. Key concall…
- ZYDUSLIFE (Q2 FY26)
Branded formulations in India growing ahead of market at 9% YoY, driven by chronic, cardiology, gynecology, and oncology therapies. Key concall takeaways from…
Frequently Asked Questions
What were Acutaas Chemicals Ltd Q2 FY26 results?
The company targets a 25% revenue growth for the full year FY '26, maintaining confidence despite achieving 21% growth in H1 FY '26. The company expects sustainable EBITDA margins of 28% to 30% in FY '26 and beyond, driven by improved product mix, higher contribution from CDMO business, and operational efficiencies (Page 14). - Revenue growth guidance is maintained at around 25% for FY '26, backed by a robust CDMO pipeline, pharmaceutical intermediates, and new verticals like electrolyte additives and semiconductor chemicals (Pages 6, 12, 14). - New CDMO products are expected to start contributing by end of FY '26, post regulatory approvals (Page 6). - Electrolyte additive plant commissioning by Q4 FY '26 and full commercial contribution expected in FY '27, with South Korea JV beginning production in H2 FY '27 (Pages 7, 14, 15). - Operational improvements and solar plant contribution are expected to support margin and profit growth (Page 6). - Capital expenditures focused on growth (INR 210 crores approx.
What is Acutaas Chemicals Ltd share price analysis?
Acutaas Chemicals Ltd currently shows a neutral. The stock trades at a P/E of 69.6 with a market cap of ₹26,877 Cr. Investors should review the full earnings analysis for detailed insights.
Is Acutaas Chemicals Ltd planning capital expenditure?
FY '26 capex planned around INR 250 crores, with INR 40 crores for maintenance and the rest for growth.
Keep Acutaas Chemicals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.